Safer contraception? new pill aims to lower artery risks
Disease control
Not yet recruiting
This phase 3 trial compares a new combined oral contraceptive pill (estetrol-drospirenone) to a standard one (ethinylestradiol-levonorgestrel) in 98 women aged 18-49. Researchers will measure artery function, blood pressure, and metabolic markers over 12 months to see if the new …
Phase: PHASE3 • Sponsor: Dr. Hang Wun Raymond Li • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC